
Yuvezzi’s Health Canada submission leads this week’s recap, plus AI front desks, the EMERALD trial, and Alberta’s scope expansion.
See our latest poll results
Optometry Times® polled our audience with the following question from March 11, 2022 to March 25, 2022:
The poll appeared on
15 ODs responded, in total. Of these:





